CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Liso-Cel Shows Durable Responses in Patients with Relapsed/Refractory CLL/SLL

December 8th 2020

December 7, 2020 - In high-risk patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, lisocabtagene maraleucel treatment resulted in a high rate of undetectable minimal residual disease with rapid and durable responses

Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in Relapsed/Refractory CD22+ B-Cell ALL

December 6th 2020

December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma

December 6th 2020

December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.

Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss

December 5th 2020

December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 5th 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

bb21217 Continues to Showcase Durable Responses in Multiple Myeloma

December 5th 2020

December 5, 2020 - The enriched chimeric antigen receptor T-cell therapy bb21217 improved responses and also prolonged duration of response compared with non-enriched CAR T cells in patients with relapsed/refractory multiple myeloma.

Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

December 1st 2020

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25th 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Panelists Parse Out Answers to Key Questions in Hematologic Malignancies

November 25th 2020

Stephen A. Strickland, MD, BS, MS, MSCI, relays insightful questions from the audience to the speakers, who provided insight into how they are navigating the evolving treatment landscape of hematologic malignancies.

CAR T-Cell Therapy Transforms Leukemia and Lymphoma Treatment, But Toxicity Concerns Remain

November 24th 2020

Olalekan O. Oluwole, MBBS, MD, discusses the approvals of tisagenlecleucel and axicabtagene ciloleucel, along with several research efforts that have been dedicated to the development and exploration of CAR T-cell therapies in the realm of leukemias and lymphomas.

FDA Lifts Clinical Hold on MELANI-01 Trial With CAR T Product UCARTCS1 in Myeloma

November 18th 2020

November 18, 2020 - The FDA has decided to lift the clinical hold placed on the phase 1 MELANI-01 trial, which is examining the CAR T-cell therapy UCARTCS1 as a treatment for patients with relapsed/refractory multiple myeloma.

COVID-19 Delays FDA Review of Liso-Cel for Relapsed/Refractory Large B-Cell Lymphoma

November 17th 2020

November 17, 2020 - The review of the biologics license application for the CAR T-cell product lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.

CAR T-Cell Research Surges

November 16th 2020

Hundreds of trials are under way, 3 CAR T-cell therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma.

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

November 10th 2020

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

The Future of CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma

November 6th 2020

Impact of COVID-19 on CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

Real-World Data for CAR T-Cell Therapy for R/R DLBCL

November 6th 2020

CAR T-Cell Therapy Clinical Trials for R/R DLBCL

November 6th 2020

Mechanism of CAR T Cells in R/R Diffuse Large B-Cell Lymphoma

November 6th 2020

Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

November 6th 2020